Featured Research

from universities, journals, and other organizations

Survival disparities in African-American and white colorectal cancer patients

Date:
October 13, 2011
Source:
Journal of the National Cancer Institute
Summary:
African-American patients with resected stage II and stage III colon cancer experienced worse overall and recurrence-free survival compared to whites, but similar recurrence-free intervals, according to a new study.

African-American patients with resected stage II and stage III colon cancer experienced worse overall and recurrence-free survival compared to whites, but similar recurrence-free intervals, according to a study published Oct. 12 in the Journal of the National Cancer Institute.

Colorectal cancer is a leading cause of cancer-related deaths in the United States. In 2006, there were an estimated 146,970 new cases of colorectal cancer diagnosed in the U.S. Of those diagnosed, 15,000 were projected to occur in individuals of African ancestry, resulting in approximately 7,000 deaths. Despite overall improvements in colorectal cancer survival in the U.S., the survival difference between African-Americans and whites has not narrowed. The 5-year relative survival rates for black and white colorectal cancer patients between 1999 and 2005 were 57% and 68%. Although several causes of the disparities have been identified, the reasons are not well understood.

In order to determine the disparities of colorectal cancer survival outcomes between blacks and whites, Greg Yothers, Ph.D., of the National Surgical Adjuvant Breast and Bowel Project Biostatistical Center and colleagues, examined data from the Adjuvant Colon Cancer ENdpoinTs (ACCENT) collaborative group database to analyze 14,611 African-American and white patients with stage II or III colorectal cancer enrolled in 12 phase III randomized controlled clinical trials conducted in North America from 1977-2002. Within these trials, patients received the same adjuvant colon cancer therapy regardless of race, but care for other diseases or recurrent colon cancer was outside the scope of these trials. The researchers evaluated overall survival, recurrence-free survival (time to recurrence or death), and recurrence-free interval (time to recurrence).

The researchers found that the five-year overall survival rate was worse among the 1,218 African-American patients, compared to the whites, with a 4.6 percentage point decrement in 5-year survival, and a 3.7 percentage point decrement in recurrence-free survival. But there was no statistically significant difference in recurrence-free interval.

The authors write that the survival differences are most likely because of factors unrelated to a patient's response to adjuvant treatment. "Black patients with resected stage II and III colon cancer treated with identical adjuvant therapy experienced poorer overall and recurrence-free survival but similar recurrence-free interval compared with white patients," they write. "Biological differences, differences in general health, and disparities in health care outside the clinical trial are possible explanations for these findings…"

In an accompanying editorial, Olufunmilayo I. Olopade, M.D., Director of the Center for Clinical Cancer Genetics & Global Health at the University of Chicago, and colleagues write that the Yothers study is consistent with studies published in the last decade. "When treated equally, African-Americans have similar colon cancer-specific survival but continue to have poorer overall survival compared with white patients," they write. Going forward, trials must include basic information on patients' socio-demographic situation, as well as their tumor biology and co-morbid conditions, the editorialists write, adding that primary care of survivors should also be improved and monitored so that differences in survival after recurrence can be better understood. Lastly, trials examining genetic markers may require enrolment targets, so that a trial could close to accrual for whites but may remain open for African-Americans and other minorities. The editorialists write, "We have documented racial and ethnic differences in cancer survival by looking from 10,000 feet over the past decade, but it is past time for us to get out of the clouds and collect and integrate data that advance the field."


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Journal References:

  1. Greg Yothers, Daniel J. Sargent, Norman Wolmark, Richard M. Goldberg, Michael J. O’connell, Jacqueline K. Benedetti, Leonard B. Saltz, James J. Dignam, A. William Blackstock, on behalf of the ACCENT Collaborative Group. Outcomes Among Black Patients With Stage II and III Colon Cancer Receiving Chemotherapy: An Analysis of ACCENT Adjuvant Trials. Journal of the National Cancer Institute, 2011; DOI: 10.1093/jnci/djr310
  2. Blase N. Polite, Brooke E. Sylvester, Olufunmilayo I. Olopade. Race and Subset Analyses in Clinical Trials: Time to Get Serious About Data Integration. Journal of the National Cancer Institute, 2011; DOI: 10.1093/jnci/djr382

Cite This Page:

Journal of the National Cancer Institute. "Survival disparities in African-American and white colorectal cancer patients." ScienceDaily. ScienceDaily, 13 October 2011. <www.sciencedaily.com/releases/2011/10/111012161302.htm>.
Journal of the National Cancer Institute. (2011, October 13). Survival disparities in African-American and white colorectal cancer patients. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/10/111012161302.htm
Journal of the National Cancer Institute. "Survival disparities in African-American and white colorectal cancer patients." ScienceDaily. www.sciencedaily.com/releases/2011/10/111012161302.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins